Cardio-metabolic benefits of quercetin in elderly patients with metabolic syndrome
Abstract
Abstract Background Quercetin is regarded as a promising phytochemical in treating metabolic syndrome (MetS). Methods Present study is a randomized, placebo-controlled, double-blind clinical trial aimed at evaluating effects of quercetin on different aspects of MetS in patients aged 60 + . Study participants consumed two quercetin-containing or placebo tablets 3 times per day (daily dose = 240 mg) during 3 months. Results Quercetin administration decreased body weight (−0.32 kg; p = 0.007) and body mass index (−0.12 kg/m2; p = 0.01). The blood pressure was also decreased: systolic blood pressure: −7.7 mm Hg (p Conclusion These findings indicate that quercetin may be effective in treating MetS. This trial was registered by Ukrainian Registry of Clinical Trials on October 30, 2017 (registration №1339).
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Quercetin Influences Quorum Sensing in Food Borne Bacteria: In-Vitro and In-Silico Evidence
- Phenolic-protein interactions: insight from in-silico analyses – a review
- In Silico Discovery of Candidate Drugs against Covid-19
- Neuropharmacological Effects of Quercetin: A Literature-Based Review
- In vitro and in silico anti-dengue activity of compounds obtained from Psidium guajava through bioprospecting
- Effect of Quercetin Rich Onion Extracts on Bacterial Quorum Sensing
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.